Supply of Delgocitinib (DOE)

This tender is for the supply of the pharmaceutical product Delgocitinib, specified with the designation (DOE). The tender likely pertains to a healthcare provider, hospital pharmacy, or a public health authority seeking to procure this medication. Delgocitinib is a Janus kinase (JAK) inhibitor used in the treatment of certain inflammatory conditions, particularly atopic dermatitis. The tender implies a need for a reliable supplier capable of providing this specific drug in the required quantities and according to specified quality standards. The designation (DOE) might refer to a specific formulation, dosage, or a particular procurement framework. The successful bidder will be responsible for the timely delivery of Delgocitinib, ensuring it meets all regulatory and quality requirements for pharmaceutical products. This procurement is critical for patient treatment and care within the healthcare system.

This is a supplies contract in the health and medical services sector, with a focus on Hospitals and Pharmaceuticals. Located in Spain, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.